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Abstract: In this study, Mn-dipyridoxaldiphosphate 
(MnDPDP),  a clinically approved manganese contrast 
agent for hepatic and pancreatic imaging,  was 
demonstrated for the first time for manganese-enhanced 
MRI (MEMRI) in brains of normal young rats (n=4) and 
rats with  hypoxic-ischemic (H-I) insult at postnatal day 7 
(n=8).  After a single intraperitoneal injection of low 
dosage with 0.1μmol/g in postnatal 14 days, 2D 
T1-weighted image (T1WIs), T1 maps, T2-weighted 
images (T2WIs) and T2 maps were acquired at 7 Tesla 1 
day before, 1 day and 7 days after MnDPDP injection. 
The image contrast changes induced by MnDPDP 
appeared as the hyperintensity in T1WIs and the 
hypointensity in T2WIs. T1and T2 values decreased in 
the regions of Mn enhancement. Such enhancement 
presented as a delayed pattern that was more pronounced 
in 7 day after MnDPDP injection, suggesting the 
sustained Mn accumulation due to MnDPDP. Moreover, 
the MnDPDP enhancement in H-I brains was more 
pronounced in the lesion sites and was easily detectable in 
T1WI, T1 map, T2WI and T2 map. The results 
demonstrated here support the possibility of using 
MnDPDP as a ‘slow release’ Mn2+ for clinical diagnosis of 
various neuropathologies.  
I. INTRODUCTION 
IV
ca
ALENT manganese ion (Mn2+) as an analogue for 
lcium ion (Ca2+) has been used as a MRI contrast 
agent to detect neuronal activation[1, 2], neural architecture[3, 
4], and neuronal connections [5, 6]. It is also essential to the 
development and function of the brain in physiological and 
pathological states [7-10]. Mn metal is bound to glutamine 
synthetase (GS) which is a glial specific enzyme for 
regulating the extracellular glutamate and ammonia. It can 
also reduce glutamate excitotoxicity [11-13] and to the 
mitochondrial Mn-superoxide dismutase (Mn-SOD) enzyme 
which acts against cellular oxidative stress [11, 14, 15]. 
Therefore, a previous study found that endogenous Mn in the 
form of Mn-SOD and GS were accumulated in delayed 
neurodegenerated regions and could be detected by MRI in 
adult rat and human after experiencing stroke [11]. Recently, 
our studies demonstrated that exogenous Mn could provide 
enhanced MRI detection of oxidative stress  and  gliosis in 
neonatal rats with hypoxia-ischemia (H-I) and adult rats with 
focal photothrombotic cortical injury and  transient  middle  
cerebral  artery  occlusion [16-18]. Especially the 
upregulation of MnSOD  and GS activities in gray matter 
with delayed neurodegeneration were observed in neonatal 
rats with mild H–I injury, leading  to  Mn-enhanced  MRI  
(MEMRI) detection of lesions undetectable by other MR 
modalities[18]. It suggests the potential usage of MEMRI by 
Mn
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2+ agent for clinical diagnosis of various 
neuropathologies. 
 Although neurotoxicity is a critical barrier to application 
of Mn2+ as a useful MRI contrast agent in clinical diagnosis, a 
chelated Mn2+ contrast agent, Mn-dipyridoxaldiphosphate 
(MnDPDP), is necessary to decrease the high acute toxicity of 
the free metal ions. It has been clinically approved for hepatic 
and pancreatic imaging for several years[19, 20], and also for 
assessments of myocardial function and viability in animal 
models[21]. This chelate gradually releases Mn2+ in presence 
of trans-metallation with zinc which is a Mn analog, allowing 
the detection of abnormalities by Mn2+ enhancement. 
MnDPDP has also been shown of certain virtue with 
antioxidative and cardioprotective properties[22]. In this 
study, we attempt to test the feasibility of delayed MnDPDP 
administration for detection of cerebral degeneration in H-I 
rats. It may open the possibility of a future study of MnDPDP 
as a ‘slow release’ Mn2+ agent for clinical diagnosis of 
various neuropathologies. 
II. MATERIALS AND METHODS 
Animal preparation 
All animal experiments were approved by the local 
animal research ethics committee. Pregnant Sprague–Dawley 
rats were obtained approximately 2 days before parturition, 
and their litters were culled to 9 to 13 pups. Neonate rats were 
kept with their mother in regular light/dark cycle for 7 days 
after birth (P7). The P7 rats, ranging from 12 to 16 g in weight, 
underwent unilateral ligation of right common carotid artery 
(double ligation followed by severing the artery in between) 
via a midline neck incision after anesthesia with 0.2 mL of 
inhalational isoflurane [17, 23-25]. The surgery took 
approximately 5 min per pup, after which the pups were kept 
in an incubator for observation at 34 °C for about 10–15 min. 
On regaining normal movements, they were returned to their 
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mother for nursing for 1 h. These pups were subsequently 
placed in a hypoxic chamber of 8% O2/92% N2 maintained at 
ambient temperatures 36 °C for 1.5 h. Among a total of 16 P7 
rats, 12 rats underwent H-I insult, among which four died 
during surgery or anoxia. Four rats were used as 
sham-operated controls; their left carotid artery was simply 
isolated and there was no exposure to hypoxia. The neonatal 
rats (N =12) were then divided into two groups. Group 1 (N 
=8): H-I insult with intraperitoneal (IP) MnDPDP 
administration; Group 2 (N = 4): sham controls (without H-I 
insult) with IP MnDPDP administration. MnDPDP with 
10μmol/mL (Teslascan®, Nycomed Imaging AS, Oslo, 
Norway) was injected at dosage of 0.1μmol/g by 
intraperitoneal route in P14 while the rats were anesthetized 
with 1% isoflurane mixed with room air. This dosage is far 
lower than the human dosage (5μmol/kg) according to 
converted method of body surface area calculation 
(equivalent dosage ratio between the human and P14 young 
rat is approximately 378). Among all rats undergoing 
MnDPDP administration, no abnormal behavior was 
observed after IP injection. 
MRI protocol 
All MRI experiments were performed on a 7-Tesla MRI 
scanner with maximum gradient of 360 mT/m (70/16 
PharmaScan, Bruker Biospin GmbH, Germany) using a 23 
mm mouse brain coil (for rats of 3 weeks old or younger) and 
a 38 mm rat brain coil (for rats older than 3 weeks). During 
the MRI scan, the rats were positioned in a plastic holder and 
anesthetized by isoflurane (1–1.5vol % at 0.8–1 L/min air 
flow via a nose cone) with respiratory monitoring. 2D 
T1-weighted images (T1WIs), T1 maps, T2-weighted images 
(T2WIs) and T2 maps were scanned in succession in P10, P14, 
P15, P21. Standard multislice coronal images were obtained 
with FOV= 2.5 cm, slice thickness= 0.5 mm, matrix size= 256
×256, voxel size= 98μm×98μm×500μm, and 20 slices. 
T1WI were acquired by a fast spin echo (FSE) sequence with 
TR= 500 ms, TEeff  =7 ms, echo train length (ETL)= 2, 
number of averages (NSA)= 6, and acquisition time= 5 min. 
T2WI were acquired using an FSE sequence with TR = 6000 
ms, TEeff = 60 ms, ETL= 12, NSA= 2, and acquisition time= 3 
min. The T2 maps were acquired by a multislice and 
multiecho SE sequence, Bandwidth= 65789Hz, TR= 3450ms, 
Echo effective= 10 ms, Echo spacing= 10 ms, Number of 
echo= 16, NSA= 1, Scan time= 11min. The corresponding T1 
maps were acquired by a saturation recovery method with a 
standard multislice spin-echo sequence, 
Bandwidth=83333Hz, Five different TR values= 3200, 1600, 
800, 400 and 200 ms, TE= 7.2 ms, NSA= 1, Spatial 
resolution= 98×125μm/pixel, FOV= 2.5×2.5 cm, slice 
thickness= 1 mm, matrix= 200 × 256, scan time= 
15min30sec. 
Data analysis 
Images were analyzed using the public domain software 
ImageJ (National Institutes of Health [NIH], Washington, DC, 
USA) and ParaVision (Bruker Biospin GmbH, Germany). 
Region of interest (ROI) analysis of the T1 maps and T2 map 
was performed and defined in specific brain regions after 
comparing the coronal images with a rat brain atlas. Three 
brain regions were analyzed: hippocampus, thalamus, and 
cortex. Mean  values  were  compared  using  two-tailed  
Student’s  t-tests,  and  the  values  along  the  time  course 
were  compared  using ANOVA. Results were considered to 
be significantly different when p<0.05. All statistical 
analyses were performed by using the statistical package 
SPSS for Windows (SPSS Inc., IL, USA). The results were 
presented as mean±SEM.  
III. RESULTS AND DISCUSSION 
MEMRI in normal young rats by IP injection of MnDPDP 
After 1 day post-MnDPDP-injection, the contrast and 
signal enhancement were observed throughout the brain in 
T1WI images, suggesting Mn2+ release by MnDPDP was 
distributed throughout the brain. Higher contrast was 
observed in the periventricular regions, caudate-putamen, 
thalamus, the hippocampus, the olfactory bulb and 
cerebellum, which was consistent with a previous study 
regarding MEMRI in young rat brain during postnatal 
development[26]. In this study, the shortened percents of T1 
value in cortex, thalamus and hippocampus were 10.4%, 
17.3% and 15.5% respectively in 1 day 
post-MnDPDP-injection. Such changes in T1 value were  
statistically  significant (ANOVA, p>0.05) when  compared  
to  the  same regions  in  the  normal  rats  before MnDPDP 
injection (see Fig.1). However, these MnDPDP-induced 
changes were noticeably smaller than the reports in several 
previous studies [26, 27], which are related to the low dosage 
of manganese used in current study, and the lower absorption 
of MnDPDP in brain comparing with MnCl2 [28].  Moreover, 
Mn accumulation in brain from MnDPDP is constant for 
more than 2 weeks[28]. Thus, further decreases of T1 value in 
cortex, thalamus and hippocampus (shortened percents: 
12.8%, 19.6% and 18.9% respectively) were found in 7 day 
post-MnDPDP–injection (see Fig.1), and that decreases of  
T2 value in cortex and thalamus were statistically  significant 
(ANOVA, p>0.05) only during 7 day post- 
MnDPDP–injection when  compared  to  the  same regions  in  
the  normal  rats  before MnDPDP injection(see Fig.2). 
MEMRI detection of Neurodegeneration in H-I young rats 
by IP injection of MnDPDP 
All 8 neonatal rats induced with medium H–I injury 
exhibited lesions on the parietal cortex and striatum with 
distinct atrophy in the hemisphere ipsilateral to carotid artery 
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ligation side (see Fig.3). At day 7 after H-I insult (P14), the 
lesion sites could not be detected in T1WIs before MnDPDP 
administration. But some lesions in subcortical white matter 
were presented as hyperintensity in T2WIs and T2 maps (the 
red arrows in Fig. 3), which was consistent with a previous 
study [29]. Moreover, some weak dark contrast also appeared 
in the ispilateral cortex (the yellow arrows in Fig. 3) and/or 
striatum in T2WIs and T2 maps, which is likely resulted from 
the endogenous iron accumulation due to an abnormal iron 
metabolism in HI injury[17]. Such decreases in T2 value were 
statistically significant (t test, p>0.001) when compared to the 
same regions in the contralateral side (see Fig.4). 
 
Fig. 1 The changes of T1 value in postnatal normal rat brains after IP 
injection of MnDPDP (n=4). 
 
Fig. 2 The changes of T2 value in postnatal normal rat brains after IP 
injection of MnDPDP (n=4). 
 
Fig. 3  Typical T1WIs, T1 maps, T2WIs and T2 maps in young rat brain 
of H-I injury before and after systemic MnDPDP administration. 
       At 1 day after MnDPDP injection (P15), some weak 
bright regions became visible in ispilateral cortex and 
striatum in T1WIs, suggesting MnDPDP induced 
enhancement, and that most spatially corresponded to regions 
with new dark contrast in T1 maps, T2WIs and T2 maps (the 
white arrows indicated in middle two rows of Fig. 3). 
Moreover, the decreases of T1 value in ipsilateral cortex and 
thalamus were statistically significant (ANOVA, p>0.001) 
when compared to the same regions prior to MnDPDP 
injection (see Fig.5). However, such decreases of T2 value 
were not statistically significant different in comparison with 
the data before MnDPDP injection (Fig.4). It suggests that 
MnDPDP induced change in T1 value is more significant 
than it is in T2 value. 
 
 
Fig. 4 The changes of T2 value in H-I rat brains after IP injection of 
MnDPDP (n=8). 
 
Fig. 5  The changes of T1 value in H-I rat brains after IP injection of 
MnDPDP (n=8). 
After 7 days post-MnDPDP-injection (P21), the Mn2+ 
induced contrast changes in ipsilateral cortex and striatum 
were further enhanced in T1WIs, T1 maps, T2WIs and T2 
maps (the white arrows indicated in below two rows of Fig. 3). 
In Fig.5, the further decreases of T1 value in ipsilateral cortex 
and thalamus were statistically significant when compared to 
the same regions in 1 day after MnDPDP injection (ANOVA, 
p>0.001) and in the contralateral side (t test, p>0.0001). The 
shortened percents of T1 value in lesion of ipsilateral cortex 
and thalamus were 29.6% and 41.7% respectively in 7 days 
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post-MnDPDP-injection and the decreases in T1 value were  
statistically  significant (ANOVA, p>0.0001) when  
compared  to  the  same regions before MnDPDP injection 
(see Fig.5). Moreover, such decreases of T2 value were 
statistically significant different in comparison with the data 
before MnDPDP injection (see Fig.4). It suggests that Mn 
accumulation from MnDPDP in lesion sites is sustained and 
MEMRI for detection of H-I lesion sites in 7 days 
post-MnDPDP-injection is more pronounced than it is in 1 
day post-MnDPDP-injection.  
 
IV. CONCLUSION 
In this study, MnDPDP as a clinically approved 
manganese contrast medium for hepatic and pancreatic 
imaging was employed for the first time for MEMRI in both 
normal and H-I young rat brains. After a single 
intraperitoneal injection of low dose at 0.1μmol/g, 
Manganese enhancement induced by MnDPDP was observed 
as delayed pattern and more pronounced in 7 days 
post-injection. Moreover, such Mn accumulation from 
MnDPDP in H-I brains was pronounced in the H-I lesion sites 
and was detectable in T1WI, T1 map, T2WI and T2 map. The 
results demonstrated here support the possibility of using 
MnDPDP as a ‘slow release’ Mn2+ agent for clinical 
diagnosis of various neuropathologies in the future. 
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